The friend within? The implantable cardioverter defibrillator between saving lives and chronically impairing them

Fausto Barlocco1

  • 1Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy.

Insights

Implantable cardioverter defibrillators (ICDs) manage cardiac risks but create ongoing challenges for patients. Living with an ICD involves navigating device limitations and societal expectations, impacting quality of life and identity.

Area of Science:

  • Medical Sociology
  • Cardiology
  • Bioethics

Background:

  • Biomedicine often overlooks patient lived experiences with chronic conditions.
  • Technological advancements like implantable cardioverter defibrillators (ICDs) are framed as victories over acute disease.
  • Chronic illness management requires understanding the patient's perspective beyond life expectancy.

Purpose of the Study:

  • To explore how implantable cardioverter defibrillators (ICDs) shape the chronicity of cardiac disease.
  • To investigate the patient experience of living with an embodied technology.
  • To examine the interplay of risk, quality of life, and choice for patients with ICDs.

Main Methods:

  • Participant observation in a clinical setting.
  • Interviews with clinicians.
  • Analysis of patient experiences with cardiac disease and ICDs.

Main Results:

  • Patients face a continuous tension managing acute cardiac risk and daily life disruptions from the ICD.
  • The concept of 'patient choice' and a 'technological imperative' to avoid risk limit patients' coping strategies.
  • Living with an ICD involves a complex process of identifying with the disease and the implanted technology.

Conclusions:

  • The focus on technological solutions and risk avoidance in cardiac care can inadvertently limit patients' ability to adapt to chronic illness.
  • Rethinking patient autonomy and the 'technological imperative' is crucial for improving the quality of life for individuals with ICDs.
  • Embodied technology significantly influences the experience and management of chronic cardiac conditions.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
51
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
43
Cardiopulmonary Resuscitation III: AED Use01:23

Cardiopulmonary Resuscitation III: AED Use

Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
94
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
128
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
75
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
772